For two decades, the answer was no.

If you were on Medicare and you wanted a medication to treat obesity — not diabetes, not heart disease, just obesity — the answer was no. It did not matter how high the BMI climbed or how many comorbidities stacked underneath it. When the Part D drug benefit launched in 2006, it carried an explicit statutory exclusion for agents used for weight loss, and that wall held through the entire rise of the GLP‑1 era. Wegovy launched. Zepbound launched. Cardiovascular and kidney outcome trials posted. And the population with the most obesity-related disease in the country watched from the wrong side of the wall.

On July 1, the wall comes down. Sort of.

Here is the part the headlines skipped. Medicare did not change the law. It cannot. Lifting that exclusion requires an act of Congress, and Congress did not act. So CMS did something stranger and more clever: it built a door beside the wall and called it a bridge.

The Medicare GLP‑1 Bridge is not Part D coverage. It is a time-limited demonstration project authorized under Section 402 of the 1967 Social Security Amendments — the same dusty provision that lets the Secretary test new payment methods to see whether they make Medicare more efficient. CMS used it to entirely circumvent the statute. The drugs are furnished outside the Part D benefit, which is the legal sleight of hand that makes the whole thing possible: if Part D never touches the claim, the Part D weight-loss exclusion never applies.

Mechanically, that means your patient's drug plan is a bystander. Plans do not opt in. Plans bear no risk. Instead, every prior authorization, every claim, and every pharmacy payment flows through a single central processor — Humana — which runs the program on the same national rails it already uses to administer emergency drug coverage for low-income beneficiaries. One processor. Every state. Every territory. Go live on day one.

"Medicare covers Ozempic now" has been the dominant headline. It is wrong. The Bridge covers exactly three things, and only when prescribed for weight management: Wegovy (the injection and the oral tablet), the KwikPen formulation of Zepbound — not the vials or single-dose pens — and Foundayo, Lilly's oral orforglipron pill, which the FDA approved on April 1 and CMS folded into the program five days later.

Ozempic, Mounjaro, and Rybelsus are nowhere on that list. Those are diabetes drugs, and they remain where they have always been: inside regular Part D, covered for diabetes. The indication on the prescription, not the molecule, decides which door a patient walks through. That distinction will generate an enormous amount of confusion at the pharmacy counter this summer, and it is worth getting ahead of it with every patient who asks.

The Bridge does not follow the FDA label, which clears these drugs at a BMI of 30, or 27 with a weight-related condition. CMS drew its own lines — three tiers, and a patient needs to satisfy only one. The prescriber attests to the tier on the prior-auth form and states that the drug is paired with ongoing nutrition and physical activity support consistent with the label.

Now, the subtle part, and the one most likely to trip up a busy clinic. The criteria are judged at the moment GLP‑1 therapy began — not at the moment you file the prior auth. CMS spells it out with its own example: a patient who started therapy in September 2024 at a BMI of 37 and walks in for a July 2026 prior authorization at a BMI of 34 still qualifies, because the prescriber attests that the BMI ≥ 35 bar was cleared at initiation. Success does not disqualify the patient. The chart that proves the starting point does.

A single price for everyone sounds like fairness. Here it is the opposite. Because the Bridge sits outside Part D, the protections built into Part D do not travel with it. The $50 does not count toward the deductible. It does not count toward the out-of-pocket cap (the figure climbs from $2,100 in 2026 to $2,400 in 2027). And the Low-Income Subsidy — Extra Help, the program that drops copays toward zero for the poorest beneficiaries, does not apply.

So a low-income senior who pays a few dollars for the rest of her medication list pays the same flat $50 here as a wealthy retiree. For someone choosing between groceries and a copay, $50 a month can be the difference between starting therapy and skipping it. The program built to widen access carries, in its design, a barrier for exactly the people who need access most. That is not a footnote. For a meaningful slice of eligible patients, it is the whole story.

Bridges are supposed to lead somewhere. This one was engineered to carry patients across a short gap into a permanent destination: the BALANCE Model, a broader CMS innovation model that would have moved GLP‑1 obesity coverage into Part D plans starting January 2027, with a wider drug list and cost-sharing that actually counted toward the out-of-pocket cap.

In April 2026, that destination was quietly shelved. BALANCE required enough Part D plans to volunteer — a threshold reportedly set around 80 percent of beneficiaries — and not enough signed up. Faced with a model nobody would join, CMS delayed the Medicare side of BALANCE indefinitely and extended the Bridge from six months to eighteen, now running through the end of 2027. The extension is genuinely good news: more runway, more certainty, more time on a $50 copay. But read what it actually is. The bridge got longer because the land on the far side disappeared.

What happens on January 1, 2028, is an open question right now. There is no confirmed Medicare pathway. BALANCE could return if CMS sweetens the terms, Congress could legislate permanent coverage, or eligible patients could simply lose access — the coverage cliff that clinicians have been quietly dreading. The Medicaid arm of BALANCE continues to roll on in participating states. The Medicare arm is a placeholder.

For all of that, the right move for most eligible patients is clear: cross the bridge. Eighteen months of effective therapy at $50 a month is a real and meaningful intervention, full stop. The catches are reasons to plan, not reasons to wait. Practically, that means three things.

One — confirm the patient belongs on the Bridge at all. If they have type 2 diabetes, obstructive sleep apnea, noncirrhotic MASH, or a covered cardiovascular indication, they are explicitly steered away from the Bridge and toward regular Part D, which is usually the better deal, because Part D dollars count toward the out-of-pocket cap and Extra Help applies. Wegovy for cardiovascular risk reduction in an eligible patient is a Part D claim, not a Bridge claim. Send the right patients through the right door.

Two — protect the documentation now. Baseline BMI, start date, and qualifying comorbidity at initiation. The whole prior-auth attestation rests on it, and for patients already mid-treatment, the chart is the only thing standing between them and a denial.

Three — counsel toward 2028 from day one. The discontinuation data is unambiguous: stop a GLP‑1 and most of the lost weight returns, with roughly two-thirds regained within a year in the semaglutide withdrawal data. A patient who crosses the Bridge without a post-2027 plan is a patient set up to regain. The conversation about what comes after the cliff should start at the first visit, not the last.

For two decades, the answer was no. For the next eighteen months, it is a qualified, conditional, time-stamped yes. That is worth celebrating — clearly, and with the fine print read out loud.

REFERENCES